Citigroup
NYMX

Citigroup’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Citigroup’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,474
Closed -$1K – 6529
2022
Q2 		$1K Sell
1,474
-107,605
-99% -$99K ﹤0.01% 6147
2022
Q1 		$137K Buy
+109,079
New +$168K ﹤0.01% 4271
2021
Q3 		– Sell
-332
Closed -$1K – 6436
2021
Q2 		$1K Sell
332
-2,799
-89% -$5.19K ﹤0.01% 6073
2021
Q1 		$7K Sell
3,131
-4,490
-59% -$11.8K ﹤0.01% 5825
2020
Q4 		$19K Buy
7,621
+5,613
+280% +$12.4K ﹤0.01% 6702
2020
Q3 		$5K Sell
2,008
-3,174
-61% -$9.24K ﹤0.01% 7061
2020
Q2 		$18K Sell
5,182
-16,788
-76% -$53.1K ﹤0.01% 6716
2020
Q1 		$51K Buy
+21,970
New +$61.7K ﹤0.01% 5968
2019
Q4 		– Sell
-3,652
Closed -$7K – 7853
2019
Q3 		$7K Sell
3,652
-1,226
-25% -$2.14K ﹤0.01% 7238
2019
Q2 		$7K Sell
4,878
-3,400
-41% -$5.95K ﹤0.01% 7408
2019
Q1 		$16K Sell
8,278
-3,774
-31% -$8.01K ﹤0.01% 7073
2018
Q4 		$16K Buy
12,052
+3,185
+36% +$5.83K ﹤0.01% 6988
2018
Q3 		$22K Buy
8,867
+1,121
+14% +$3.31K ﹤0.01% 7047
2018
Q2 		$26K Buy
7,746
+2,811
+57% +$10.8K ﹤0.01% 6793
2018
Q1 		$21K Buy
4,935
+820
+20% +$2.84K ﹤0.01% 6725
2017
Q4 		$14K Buy
4,115
+4,011
+3,857% +$14.6K ﹤0.01% 6904
2017
Q3 		$0 Sell
104
-85
-45% -$322 ﹤0.01% 7509
2017
Q2 		$1K Buy
+189
New +$776 ﹤0.01% 7240
2016
Q1 		– Sell
-82
Closed – – 7860
2015
Q4 		$0 Sell
82
-1,513
-95% -$5.08K ﹤0.01% 7948
2015
Q3 		$5K Buy
+1,595
New +$3.71K ﹤0.01% 6763
2014
Q2 		– Sell
-212
Closed -$1K – 7371
2014
Q1 		$1K Buy
212
+179
+542% +$1.04K ﹤0.01% 6905
2013
Q4 		$0 Buy
+33
New +$225 ﹤0.01% 7198

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Citigroup's NYMX Position: Q3 2022 in Review

Citigroup sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2022, closing a stake of 1,474 shares — an estimated $1K sold.

Citigroup first reported a position in NYMX in Q4 2013 and held it in 22 quarters. The position peaked at $137K in Q1 2022. 34 funds tracked by Wall St. Rank hold NYMX as of Q3 2022.

  • Citigroup reported no remaining Nymox Pharmaceutical Corp position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 1,474 Nymox Pharmaceutical Corp shares in Q3 2022, an estimated $1K.
  • Citigroup first reported a position in Nymox Pharmaceutical Corp in Q4 2013 and held it in 22 quarters.
  • Citigroup's Nymox Pharmaceutical Corp position peaked at $137K in Q1 2022.
  • 34 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.